Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.35 |
| ▸ | STAT3 | P40763 | 3/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.33 |
| ▸ | NTRK3 | Q16288 | 3/20 | 0.33 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tba-354 SCHEMBL29422222 | 1.00 | CHRM1 (0.81) | CHRM1KCNH2PTGS1SLC6A2SLC6A4 | |
| SCHEMBL508066 | 0.91 | CHRM1 (0.94) | CHRM1KCNH2PTGS1SLC6A2SLC6A4 | |
| SCHEMBL508717 | 0.90 | CHRM1 (0.80) | CHRM1KCNH2PTGS1SLC6A2SLC6A4 | |
| Pretomanid SCHEMBL14004006 | 0.90 | CHRM1 (1.00) | CHRM1KCNH2PTGS1SLC6A2SLC6A4 | |
| Pretomanid SCHEMBL2983011 | 0.90 | CHRM1 (1.00) | CHRM1KCNH2PTGS1SLC6A2SLC6A4 | |
| SCHEMBL508058 | 0.89 | CHRM1 (0.62) | CHRM1KCNH2GRM2NTRK1NTRK3 | |
| SCHEMBL508172 | 0.89 | CHRM1 (0.72) | CHRM1KCNH2PTGS1SLC6A2SLC6A4 | |
| SCHEMBL508760 | 0.88 | CHRM1 (0.65) | CHRM1KCNH2PTGS1SLC6A2SLC6A4 | |
| SCHEMBL508569 | 0.88 | CHRM1 (0.64) | CHRM1KCNH2PTGS1SLC6A2SLC6A4 | |
| SCHEMBL1160458 | 0.87 | CHRM1 (0.94) | CHRM1KCNH2PTGS1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9198913-B2 | Nitroimidazooxazines and their uses in anti-tubercular therapy | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2015-12-01 | — | — | US | claimed |
| EP-2459571-B1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEV (US) | 2015-03-11 | — | — | EP | claimed |
| CN-118994196-A | Polycyclic carbamoyl pyridone derivatives, process for preparing the same and pharmaceutical compositions containing the same | 南京艾迪医药科技有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-116120342-B | Polycyclic carbamoyl pyridone derivatives, process for preparing the same and pharmaceutical compositions containing the same | 南京艾迪医药科技有限公司 | 2024-08-30 | — | — | CN | disclosed |
| CN-118384165-A | Pharmaceutical preparation and preparation method and application thereof | 成都艾迪医药技术有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-117327092-A | Method for purifying doravir intermediate | 上海迪赛诺化学制药有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-116270699-A | Three-party preparation, preparation method and application | 上海复星医药产业发展有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116171280-A | Casein kinase 1 delta modulators | 詹森药业有限公司 | 2023-05-26 | — | — | CN | disclosed |
| CN-116120342-A | Polycyclic carbamoyl pyridone derivatives, process for preparing the same and pharmaceutical compositions containing the same | 南京艾迪医药科技有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-115461120-A | Sulfonylimide compounds as NLRP3 modulators | 豪夫迈·罗氏有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-115448908-A | Compounds for the treatment of specific leukemias | 拓臻股份有限公司 | 2022-12-09 | — | — | CN | disclosed |
| US-9198913-B2 | Nitroimidazooxazines and their uses in anti-tubercular therapy | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2015-12-01 | — | — | US | disclosed |
| US-9198913-B2 | Nitroimidazooxazines and their uses in anti-tubercular therapy | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2015-12-01 | — | — | US | disclosed |
| US-9198913-B2 | Nitroimidazooxazines and their uses in anti-tubercular therapy | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2015-12-01 | — | — | US | disclosed |
| EP-2459571-B1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEV (US) | 2015-03-11 | — | — | EP | disclosed |
| EP-2459571-B1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEV (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2011014774-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | NOX5, MT-ND5, NQO1 | CHRM1 1375/4885KCNH2 3157/4885PTGS1 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.